The world is racing to find safe and effective vaccines against COVID-19. And when we do, these vaccines must be made available to everyone who needs them regardless of nationality or wealth. Not only is this morally right but it is also the fastest way to end the pandemic. So as world leaders line up to make deals for COVID-19 vaccines candidates we want to know: did this deal move us closer to, or further from, an equitable outcome?

The Vaccine Access Test provides a framework to answer this question by evaluating deals between companies and countries using three metrics:

➔ Prioritized: Is this deal aligned with global guidelines on prioritizing allocation among at-risk populations?
➔ Phased: Does this deal allow for phased delivery of doses to ensure initial-supply is not monopolized?
➔ Published: Is the contracting processes transparent from start to finish?

Each metric is worth up to 2 points with the potential for 6 points total. Here is how this deal stacks up.

**DEAL SUMMARY**

**Parties:** Valneva and United Kingdom

**Date:** September 14, 2020

**Terms of Agreement:** The United Kingdom signed an agreement with Valneva for 60 million doses at a cost of €470 million with options over another 130 million doses between 2022 and 2025. The UK Government invested in Valneva’s manufacturing facility in Livingston, Scotland, to support scale up, creating a major UK vaccine facility.

<table>
<thead>
<tr>
<th>METRIC</th>
<th>SCORE</th>
<th>RATIONALE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prioritized</td>
<td>0</td>
<td>60m doses would cover over 45% of the UK’s population with a 2-dose regimen, exceeding the 3% initial allocation threshold and the threshold to prioritize the most vulnerable 20% population.</td>
</tr>
<tr>
<td>Phased</td>
<td>2</td>
<td>Valneva will provide the UK government with 60 million doses in the second half of 2021. UK Government then has options over 40 million doses in 2022 and a further 30 million to 90 million doses, in aggregate, across 2023 to 2025. Ideally, deals will allow for other countries to benefit from the initial supply and tier delivery of subsequent supply as it becomes available.</td>
</tr>
<tr>
<td>Published</td>
<td>0</td>
<td>The UK has not listed details about the terms of deal and pricing online. Valneva has not disclosed their pricing model.</td>
</tr>
</tbody>
</table>

**Total Score: 2 out of 6**

This deal leaves some flexibility to ensure the initial supply of vaccines isn’t monopolized by the UK.

Subsequent deals could be improved by purchasing against global population allocation guidelines. Valneva could also disclose a break-down of how they arrived at their unit price, and what it costs to produce the vaccine. We will also be watching to ensure additional doses aren’t purchased before other countries have secured deals for portions of the initial supply.

Check out the full methodology and scores for other deals, countries, and companies at ONE.org/VaccineAccessTest